Baxter International has filed an amended biologics license application (BLA) to the US Food and Drug Administration (FDA) to re-start the review process for approval of HyQvia facilitated subcutaneous infusion to treat adult patients with ...
Halozyme Therapeutics has entered into collaboration and license agreement with Pfizer for the development and commercialization of subcutaneous biologics. The collaboration will focus on developing Pfizer biologics, leveraging Halozyme's ...
Tags: biologics, Halozyme Therapeutics, subcutaneous biologics, treatments